CERo Therapeutics Holdings, Inc. Common Stock (CERO) - Total Assets
Based on the latest financial reports, CERo Therapeutics Holdings, Inc. Common Stock (CERO) holds total assets worth $3.91 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of CERo Therapeutics Holdings, Inc. Common for net asset value and shareholders' equity analysis.
CERo Therapeutics Holdings, Inc. Common Stock - Total Assets Trend (2021–2024)
This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
CERo Therapeutics Holdings, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
CERo Therapeutics Holdings, Inc. Common Stock's total assets of $3.91 Million consist of 59.8% current assets and 40.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 53.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CERO market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CERo Therapeutics Holdings, Inc. Common Stock's current assets represent 59.8% of total assets in 2024, an increase from 0.8% in 2021.
- Cash Position: Cash and equivalents constituted 53.6% of total assets in 2024, up from 0.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
CERo Therapeutics Holdings, Inc. Common Stock Competitors by Total Assets
Key competitors of CERo Therapeutics Holdings, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
CERo Therapeutics Holdings, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.30 | 0.39 | 24.00 |
| Quick Ratio | 0.30 | 0.39 | 24.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.90 Million | $-5.71 Million | $23.00K |
CERo Therapeutics Holdings, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between CERo Therapeutics Holdings, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 21.1% |
| Total Assets | $6.21 Million |
| Market Capitalization | $717.49K USD |
Valuation Analysis
Below Book Valuation: The market values CERo Therapeutics Holdings, Inc. Common Stock's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CERo Therapeutics Holdings, Inc. Common Stock's assets grew by 21.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CERo Therapeutics Holdings, Inc. Common Stock (2021–2024)
The table below shows the annual total assets of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.21 Million | +21.08% |
| 2023-12-31 | $5.13 Million | -87.90% |
| 2022-12-31 | $42.37 Million | -76.47% |
| 2021-12-31 | $180.08 Million | -- |
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.